NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

NCT06780150

RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Multiple Sclerosis

Interventions: Ocrelizumab

Countries: Germany, Switzerland

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of MS
* RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024
* First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab

Exclusion Criteria:

* Participation in interventional studies investigating DMTs for MS
* Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
* Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
* Severe psychiatric disability
* Pregnant women

Locations (92)

Aachen, Germany
Amberg, Germany
Arnsdorf, Germany
Aschaffenburg, Germany
Bad Soden, Germany
Bamberg, Germany
Berg, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Bochum, Germany
Bogen, Germany
Buchholz, Germany
Celle, Germany
Celle, Germany
Chemnitz, Germany
Cologne, Germany
Dortmund, Germany
Düsseldorf, Germany
Düsseldorf, Germany
Düsseldorf, Germany
Eltville, Germany
Erbach/Odenwald, Germany
Erlangen, Germany
Essen, Germany
Essen, Germany
Forchheim, Germany
+ 62 more on CT.gov